Penn Center for Cancer Care Innovation (PC3I) Director Justin Bekelman, MD, is quoted by The Wall Street Journal in a major article on the risk of death from COVID-19 among patients with cancer–both active and in remission. A new study in The Lancet of 928 COVID-19 patients in the U.S., Canada, and Spain suggests that the death rate in cancer patients with COVID-19 is significantly higher than in the general population. The study found that 13% of COVID-19 patients with cancer that was either active or in remission died within 30 days of diagnosis with the novel coronavirus, more than double the 5.9% death rate in the general U.S. population.
“This study confirms the idea that patients with cancer are at a higher risk of sickness and death from Covid-19,” PC3I Director Justin Bekelman, MD, told The Wall Street Journal.
Reflecting on 50 years of the National Cancer Act, PC3I Faculty Ravi Parikh shares his thoughts with AARP on new cancer treatments and improvements in managing treatment side effects.
Dr. Christine Edmonds and PC3I Faculty Dr. Lola Fayanju share several ways in which Black women experience socioeconomic barriers and systemic biases that impact breast cancer treatment and survival.
Researchers from the Population-based Research to Optimize the Screening Process (PROSPR) Consortium are working to eliminate disparities in uptake of lung cancer screening.